We identified 49 patients who were treated with metformin during the course of their care, and found that increased expression of N-cadherin and p-p65 and reduced expression of AMPK were each associated with higher likelihood of prostate cancer recurrence (Table 1 and Fig. S1P < 0.05). The gene discussed is PRKAA1; the disease is prostate cancer.